Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials
Alessandro Battaggia, Alberto Donzelli, Maria Font, Davide Molteni, Antonio Galvano, Alessandro Battaggia, Alberto Donzelli, Maria Font, Davide Molteni, Antonio Galvano
Abstract
Background: Randomized clinical trials (RCTs) about Ezetimibe's efficacy on patient-oriented outcomes have given discordant results. The aim of this study was to determine the net effect of Ezetimibe and of the widely marketed combination, Ezetimibe+simvastatin, on mortality and morbidity outcomes.
Methods and findings: We searched for RCT on Ezetimibe using MEDLINE, CCTR, EMBASE, ClinicalTrials.gov databases up to December 2013, Merck and Novartis online registers, and personal communications. Two authors independently selected trials fulfilling these criteria: RCTs comparing Ezetimibe±statin or another lipid-lowering drug against placebo, or against the same lipid-lowering drug at the same dosage, with a follow-up at least 24 weeks and one or more of these outcomes: all-cause mortality, cardiovascular (CV) mortality, stroke, myocardial infarction (MI), cancer, serious adverse events (SAEs); we assessed the risk of bias using the Cochrane checklist. We extracted the data for major clinical events as a dichotomous measure, with the patient the unit of analysis. Pooled analysis was done with random and fixed effect based models. Trials comparing Ezetimibe plus a lipid-lowering drug against the same lipidlowering drug representing the net effect of Ezetimibe, showed a nonsignificant tendency toward damage for cancer, MI, stroke and SAEs. Ezetimibe+simvastatin vs. simvastatin alone showed a stronger tendency towards a higher risk for all-cause death (2.52; 0.65-9.74), CV death (3.04; 0.48-19.21), non-CV death (3.03; 0.12-73.50), MI (1.91; 0.42-8.70), stroke (2.38; 0.46-12.35), cancer (RR 11.11; 0.62-198.29), and SAEs (1.45; 0.95-2.23). Limitations include small numbers of events and inadequate power of the pooling. Trials comparing Ezetimibe+simvastatin vs placebo showed non-significant effects: MI (0.81; 0.66-1.00 p = 0.051), all-cause death (1.02; 0.95-1.09), CV death (0.91; 0.80-1.04), non-CV death (108; 0.99-1.18), stroke (0.86; 0.72-1.04), cancer (1.18; 0.80-1.74), SAEs (1.01; 0.96-1.06).
Conclusions: Ezetimibe±simvastatin had inconsistent effects on important outcomes. No firm conclusions are possible, but findings indicative of damage suggest much more selective use of Ezetimibe±simvastatin.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–1443. 10.1056/NEJMoa0800742
- Supplement to: Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF et al. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–1443. 10.1056/NEJMoa0800742
- Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–1356. 10.1056/NEJMoa0804602
- Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. NEngl J Med. 2009;361:2113–2122. 10.1056/NEJMoa0907569
- Todd C. Villines TD, Stanek EJ, Devine PJ, Turco M, Miller M, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis). Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration. J Am Coll Cardiol. 2010;55:2721–2726. 10.1016/j.jacc.2010.03.017
- Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA. 2008;299:1678–1689. 10.1001/jama.299.14.1678
- Fleg JL, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008;52:2198–2205. 10.1016/j.jacc.2008.10.031
- Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis. 2006;47:385–395.
- Mascitelli L, Pezzetta F, Goldstein MR. Role of Ezetimibe in the Prevention of Cardiovascular Disease: Absence of Evidence. Arch Med Res. 2010;41:649–650. 10.1016/j.arcmed.2010.10.008
- Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet. 2001;377: 2181–2192.
- Therapeutics Initiative. Do statins have a role in primary prevention? An update. Therapeutics Letter. 2010;77:1–2.
- Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336:601–605. 10.1136/
- Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from RCTs. Ann Intern Med. 2012;157:429–438.
- Strippoli GMF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: metaanalysis and metaregression of randomized controlled trials. Cochrane Renal Group. BMJ. 2008;336:645–658. 10.1136/
- DailyMed website. Available: . Accessed 2015 March 20.
- Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Wiley-Blackwell; 2011;ISBN 978-0-470-69951-5 (H/B). Cochrane Community (beta) website. Available: . Accessed 2015 March 20.
- Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Wiley; March 2008;ISBN: 978-1-119-96437-7.
- Peters JL 1, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of Two Methods to Detect Publication Bias in Meta-analysis. JAMA. 2006;295:676–680.
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315: 629–634.
- Crowther MJ, Hinchliffe SR, Donald A, Sutton AJ. Simulation-based sample size calculation for designing new clinical trials and diagnostic test accuracy studies to update an existing meta-analysis. The Stata Journal. 2013;13:451–473.
- Higgins JPT, White IR, Wood MA. Imputation methods for missing outcome data in meta-analysis of clinical trials. Clinical Trials. 2008; 5:225–239. 10.1177/1740774508091600
- Arimura T, Miura S, Ike A, Sugihara M, Iwata A, Nishikawa H, et al. Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina. J Cardiol. 2012;60:111–118. 10.1016/j.jjcc.2012.03.002
- Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, Kostara C, Gartzonika C, Bairaktari ET et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. J Cardiovasc Pharmacol Ther. 2013;18:5–12. 10.1177/1074248412445506
- Ballantyne CM, Lipka LJ, Sager PT, Strony J, Alizadeh J, Suresh R, et al. Longterm safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract. 2004;58:653–8.
- West AM, Anderson JD, Meyer CH, Epstein FH, Wang H, Hagspiel KD, et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis. 2011;218:156–162. 10.1016/j.atherosclerosis.2011.04.005
- McKenney JM, Farnier M, Lo KW, Bays HE, Perevozkaya I, Carlson Gal, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol. 2006;47:1584–7.
- Rayner BL, Byrne MJ, Van Zyl Smit R. A Prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with Simvastatin and diet, versus diet alone. Clin Nephrol. 1996;46:219–24
- Walker RJ, Sutherland WH, Walker HL, MaMahon S, Robson RA. Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT study Collaborative Group. Nephrol Dial Transplant. 1997;12:87–92.
- Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.
- Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122.
- Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099. 10.1056/NEJMoa1206797
- Teo KK, Goldstein LB, Chaitman BR, Grant S, Weintraub WS, Anderson DC, et al. Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients With Cardiovascular Disease. The Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcome (AIM–HIGH) Trial. Stroke. 2013;44: 2688–2693. 10.1161/STROKEAHA.113.001529
- Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008;359:1357–1366. 10.1056/NEJMsa0806603
- Doggrel SA. The ezetimibe controversy—can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together? Expert Opin Pharmacother. 2012;13:1469–1480. 10.1517/14656566.2012.696098
Source: PubMed